STOCK TITAN

OS Therapies Incorporated (OSTX) Financials

OSTX NYSE
FY2025 annual
Net Income -$28.8M n/m YoY
EPS (Diluted) -$0.98 YoY not available
Free Cash Flow -$14.7M YoY not available
Operating Cash Flow -$14.2M n/m YoY
Market Cap $42.0M as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OSTX SEC filings page.

This page shows OS Therapies Incorporated (OSTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OSTX FY2025

FY2025 shows sharply higher development spending, deeper losses, and severe short-term balance-sheet pressure despite external financing.

R&D expansion reached 476.3% from FY2024 while FY2025 recorded a net loss of $28.8M and operating cash flow of -$14.2M; the much larger investment has not yet produced accounting or operating-cash breakeven. The smaller cash loss than accounting loss indicates that reported earnings include noncash or timing effects, although the supplied figures do not identify their full composition.

The balance sheet deteriorated on both liquidity and solvency measures: the current ratio fell from 1.2x in FY2024 to 0.0x in FY2025 as current assets fell 94.0% while current liabilities rose 154.2%. Liabilities of $11.9M exceeded assets of $6.8M, leaving negative equity of $6.1M.

FY2025 financing cash flow was $9.4M versus operating cash flow of -$14.2M, so funding inflows did not cover operating cash use. Free cash flow of -$14.7M despite only $466K of capital expenditures indicates that operations, rather than fixed-asset reinvestment, drove the cash deficit.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for OS Therapies Incorporated, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

OS Therapies Incorporated passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

OS Therapies Incorporated reported a net loss of $28.8M while operations used $14.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$8.9M
YoYn/m
QoQn/m

OS Therapies Incorporated's EBITDA was -$8.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$11.3M
YoYn/m
QoQn/m

OS Therapies Incorporated reported a net loss of $11.3M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.23
QoQn/m

OS Therapies Incorporated earned -$0.23 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$432K
YoY-77.0%
QoQ+110.6%

OS Therapies Incorporated held $432K in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
52M
QoQ+13.4%

OS Therapies Incorporated had 52M shares outstanding in Q3 2026. Against the prior quarter it is up 13.4%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

None of these metrics is reported for Q3 2026.

Capital Allocation

R&D Spending
$6.0M
YoY+59.1%
QoQ-1.7%

OS Therapies Incorporated invested $6.0M in research and development in Q3 2026. This represents an increase of 59.1% from the same quarter a year earlier. Against the prior quarter it is down 1.7%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

OSTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OSTX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$6.0M+59.1%$6.1M+143.0%$7.4M+461.6%$8.8M+910.6%$3.8M+210.3%$2.5M+530.3%$1.3M+261.8%$870K
SG&A Expenses$3.1M-2.0%$2.5M+6.9%$2.8M-23.7%$3.2M+52.3%$3.1M+154.6%$2.3M+510.4%$3.7M+1274.8%$2.1M
Operating Income-$9.0Mn/m-$8.6Mn/m-$10.2Mn/m-$12.0Mn/m-$6.9Mn/m-$4.8Mn/m-$5.0Mn/m-$3.0Mn/m
EBITDA-$8.9Mn/m-$8.5Mn/m-$10.0Mn/m-$11.9Mn/m-$6.8Mn/m-$4.7Mn/m-$5.0Mn/m-$3.0Mn/m
Interest Expense$621K$6K$75KN/AN/AN/AN/A$8K-97.5%
Net Income-$11.3Mn/m-$8.6Mn/m-$10.4Mn/m-$13.5Mn/m-$6.9Mn/m-$4.5Mn/m-$3.9Mn/m-$3.0Mn/m
EPS (Basic)-$0.23-$0.20-$0.27-$0.41-$0.22-$0.19-$0.18-$0.24
EPS (Diluted)-$0.23-$0.20-$0.27-$0.41-$0.22-$0.19-$0.18-$0.24
Diluted Shares (Avg)48M44M39MN/A32M25M21MN/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

OSTX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OSTX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$8.1M-9.4%$9.9M-4.0%$7.3M+71.7%$6.8M+23.5%$9.0M+352.8%$10.3M+668.2%$4.2M+305.2%$5.5M+594.0%
Current Assets$2.0M-14.9%$3.6M+2.4%$918K-77.6%$333K-94.0%$2.3M+17.8%$3.6M+166.1%$4.1M+293.2%$5.5M+600.4%
Cash & Equivalents$432K-77.0%$205K-92.7%$918K-69.1%$270K-95.1%$1.9M+1.0%$2.8M+2851.8%$3.0M+2864.2%$5.5M+14095.1%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$24.0M+465.5%$20.7M+482.9%$17.1M+102.1%$11.9M+34.7%$4.2M+58.1%$3.6M-87.5%$8.4M-68.2%$8.8M-64.5%
Current Liabilities$23.9M+476.7%$20.6M+496.9%$17.0M+379.4%$11.8M+154.2%$4.1M+60.4%$3.5M-87.8%$3.5M-86.6%$4.6M-81.3%
Non-Current Liabilities$100K0.0%$100K0.0%$100K0.0%$100K0.0%$100K0.0%$100K0.0%$100K0.0%$100K0.0%
Total Equity-$17.0M-566.5%-$11.9M-341.0%-$10.8Mn/m-$6.1Mn/m$3.6Mn/m$4.9Mn/m-$4.2Mn/m-$3.3Mn/m
Retained Earnings-$97.5Mn/m-$86.2Mn/m-$77.6Mn/m-$67.2Mn/m-$53.7Mn/m-$46.8Mn/m-$42.3Mn/m-$38.4Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

OSTX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OSTX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$4.7Mn/m-$5.5Mn/m-$4.6Mn/m-$3.7Mn/m-$4.7Mn/m-$2.4Mn/m-$3.4Mn/m-$2.4Mn/m
Depreciation & Amortization$125K0.0%$125K+11.0%$125K+17876.7%$125K+8888.3%$125Kn/m$113K+16089.1%$6950.0%$1Kn/m
Stock-Based Compensation$2.0MN/A$1.4M+52.5%N/AN/A$905K$941KN/A
Capital ExpendituresN/AN/AN/A$0$0$316K$150KN/A
Free Cash FlowN/AN/AN/A-$3.7M-$4.7M-$2.7M-$3.6MN/A
Investing Cash FlowN/AN/AN/A$0$0-$293K-$174KN/A
Financing Cash Flow$4.9M+29.1%$4.8M+94.1%$5.2M+394.9%$2.1M-64.9%$3.8M-26.6%$2.5M+183.6%$1.1M+49.8%$6.0M+576.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

OSTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OSTX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on EquityN/AN/AN/AN/A-189.1%-91.8%N/AN/A
Return on Assets-139.1%-62.3pp-87.2%-43.2pp-142.4%-51.2pp-196.8%-142.8pp-76.8%+68.6pp-44.0%+72.0pp-91.2%+47.9pp-54.0%+129.5pp
Current Ratio0.08-0.5x0.18-0.9x0.05-1.1x0.03-1.2x0.56-0.2x1.03+1.0x1.16+1.1x1.20+1.2x
Liabilities-to-EquityN/AN/AN/AN/A1.170.72N/AN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$6.1M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
OS Therapies Incorporated OSTX FY2025 N/A -$28.8M N/A $42.0M —
Dogwood Therapeutics, Inc. DWTX FY2025 N/A -$34.3M N/A $39.6M —
Annovis Bio, Inc. ANVS FY2025 $0 -$28.9M N/A $44.1M —
Corbus Pharmaceuticals Holdings, Inc. CRBP FY2025 N/A -$78.5M N/A $42.4M —
Biomea Fusion, Inc. BMEA FY2025 N/A -$61.8M N/A $41.7M —
Mereo BioPharma Group plc MREO FY2025 $500K -$41.9M N/A $41.5M —

Frequently Asked Questions

No, OS Therapies Incorporated (OSTX) reported a net loss of $28.8M in fiscal year 2025.

OS Therapies Incorporated (OSTX) reported diluted earnings per share of -$0.98 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

OS Therapies Incorporated (OSTX) had EBITDA of -$28.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

OS Therapies Incorporated (OSTX) recorded an outflow of $14.7M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

OS Therapies Incorporated (OSTX) recorded an outflow of $14.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

OS Therapies Incorporated (OSTX) had $6.8M in total assets as of fiscal year 2025, including both current and long-term assets.

OS Therapies Incorporated (OSTX) invested $466K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

OS Therapies Incorporated (OSTX) invested $16.4M in research and development during fiscal year 2025.

OS Therapies Incorporated (OSTX) had 40M shares outstanding as of fiscal year 2025.

OS Therapies Incorporated (OSTX) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

OS Therapies Incorporated (OSTX) had a return on assets of -420.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

OS Therapies Incorporated (OSTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $42.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

OS Therapies Incorporated (OSTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $42.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, OS Therapies Incorporated (OSTX) held $270K in cash, cash equivalents and investments, and reported an operating cash outflow of $14.2M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

OS Therapies Incorporated (OSTX) has negative shareholder equity of -$6.1M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

OS Therapies Incorporated (OSTX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

OS Therapies Incorporated (OSTX) reported a net loss of $28.8M while operations used $14.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top